Squarepoint
KRYS icon

Squarepoint’s Krystal Biotech KRYS Stock Holding History

Squarepoint’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
+600
New +$179K ﹤0.01% 3998
2026
Q1 		– Sell
-1,500
Closed -$370K – 4642
2025
Q4 		$370K Buy
+1,500
New +$316K ﹤0.01% 3450
2024
Q4 		– Sell
-2,600
Closed -$473K – 5290
2024
Q3 		$473K Buy
+2,600
New +$501K ﹤0.01% 3134

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Squarepoint's KRYS Position: Q2 2026 in Review

Squarepoint sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 1,138 shares — an estimated $340K sold.

Squarepoint first reported a position in KRYS in Q4 2017 and held it in 16 quarters. The position peaked at $14.8M in Q1 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Squarepoint reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 1,138 Krystal Biotech shares in Q2 2026, an estimated $340K.
  • Squarepoint first reported a position in Krystal Biotech in Q4 2017 and held it in 16 quarters.
  • Squarepoint's Krystal Biotech position peaked at $14.8M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.